The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms
Microsurgery · 2024
DOI: 10.1002/micr.31185 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Microsurgery, 2024. Verfasst von Jose A Foppiani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Mammaplasty, Perforator Flap. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Recent CMS billing changes have raised concerns about insurance coverage for deep inferior epigastric perforator (DIEP) flap breast reconstruction. This study compared the costs and utilization of transverse rectus abdominis myocutaneous (TRAM), DIEP, and latissimus dorsi (LD) flaps in breast reconstruction.
Method
The study utilized the National Inpatient Sample database to identify female patients who underwent DIEP, TRAM, and LD flap procedures from 2016 to 2019. Key data such as patient demographics, length of stay, complications, and costs (adjusted to 2021 USD) were analyzed, focusing on differences across the flap types.
Results
A total of 17,770 weighted patient encounters were identified, with the median age being 51. The majority underwent DIEP flaps (73.5%), followed by TRAM (14.2%) and LD (12.1%) flaps. The findings revealed that DIEP and TRAM flaps had a similar length of stay (LOS), while LD flaps typically had a shorter LOS. The total hospital charges to costs using cost‐to‐charge ratio were also comparable between DIEP and TRAM flaps, whereas LD flaps were significantly less expensive. Factors such as income quartile, primary payer of hospitalization, and geographic region significantly influenced flap choice.
Conclusion
The study's results appear to contradict the prevailing notion that TRAM flaps are more cost‐effective than DIEP flaps. The total hospital charges to costs using cost‐to‐charge ratio and hospital stays associated with TRAM and DIEP flaps were found to be similar. These findings suggest that changes in the insurance landscape, which may limit the use of DIEP flaps, could undermine patient autonomy while not necessarily reducing healthcare costs. Such policy shifts could favor less costly options like the LD flap, potentially altering the landscape of microvascular breast reconstruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Plastic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Plastic Surgery, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Maria J Escobar-Domingo, Bernard T Lee
Zitieren
APA
Foppiani, J. A., Hernandez Alvarez, A., Kim, E. J., Escobar-Domingo, M. J., Taritsa, I. C., Schuster, K. A., Lee, D., Ho, O. A., Rinker, B., Lee, B. T., & Lin, S. J. (2024). The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms. Microsurgery. https://doi.org/10.1002/micr.31185
Vancouver
Foppiani JA, Hernandez Alvarez A, Kim EJ, Escobar-Domingo MJ, Taritsa IC, Schuster KA, et al. The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms. Microsurgery. 2024. doi:10.1002/micr.31185
BibTeX
@article{Foppiani2024,
author = {Foppiani, Jose A and Hernandez Alvarez, Angelica and Kim, Erin J and Escobar-Domingo, Maria J and Taritsa, Iulianna C and Schuster, Kirsten A and Lee, Daniela and Ho, Olivia A and Rinker, Brian and Lee, Bernard T and Lin, Samuel J},
title = {The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms},
journal = {Microsurgery},
year = {2024},
doi = {10.1002/micr.31185}
}
EUVIMED